Introduction
Follicular helper T cells (Tfh) are a specific T cell subset providing help to B cells, thus bolstering the formation of germinal centers (GC), the generation of long-lived plasma cells and of memory B cells. In mouse and human secondary lymphoid organs, Tfh cells are characterized by the expression of CXCR5, the costimulatory molecules ICOS, PD-1 and OX40, and the transcriptional repressor Bcl-6 [1] [2] [3] . In vitro, these cells are able to induce the production of IgG, IgA and IgM when cocultured with B cells [4, 5] . In addition to the secretion of IL-21 [6] , Tfh cells function is dependent on cognate interactions between their TCR and peptide-loaded MHC class II molecules expressed on B cells [7] . The costimulatory molecules ICOS, PD-1, CD40 ligand, and SAP (signaling lymphocytic activation molecule associated protein) play a major role in facilitating the differentiation of B cells [7] [8] [9] [10] . Tfh cells differentiation and persistence are dependent on cognate B cell interactions and continued expression of Bcl-6 [11] , which can be antagonized by IL-2 signaling and transcriptional repression by Blimp-1 [12, 13] .
Nrp1 is a receptor of neural guidance cues (class 3 semaphorins) and proangiogenic factors (VEGFs) with crucial roles in the development and function of the nervous and cardiovascular systems [14, 15] . In the human immune system, in addition to being a specific marker for plasmacytoid dendritic cells (pDCs) [16] , Nrp1 has been attributed a crucial role for the primary activation of T cells by DCs [17] . In mouse, Nrp1 is expressed by recent thymic emigrant invariant NKT cells [18] and is constitutively expressed by natural Foxp3 + Treg cells [19] [20] [21] [22] [23] . However, in humans Nrp1 expression is rarely found on CD25 + Foxp3 + Treg cells [24, 25] . The majority of T cells expressing Nrp1 in vivo do not express CD25, whereas its induction on T cells in vitro is dependent on TCR activation, proliferation and expression of CD25 [25] .
Tfh cells interact with B cells in secondary lymphoid organs, but there is currently no specific T cell marker for this activity. Although the impact of cognate contacts with Tfh cells on GC B cell differentiation is the focus of intense investigation, little is known of the outcome of such interactions for Tfh cells. TCR engagement on conventional T cells induces the expression of various surface markers such as CD69, CD25 or Nrp1, which are associated with cellular activation and proliferation [25] . Although Tfh cells have little proliferative capacity after TCR stimulation and do not express CD25 during their differentiation induced by dendritic cells [2, 26] , they strongly express CD69 that would result from multiple contacts with antigen-presenting cells [7] . Additional activation markers that may be specifically induced in Tfh cells after B cell contact are lacking.
Here we characterized Nrp1-expressing T cells in human secondary lymphoid organs. We show that Nrp1 is specifically expressed by a fraction of Tfh cells in vivo, that Nrp1 expression on Tfh cells is transient and can be induced on Nrp1 -Tfh cells upon contact with autologous memory B cells in vitro. Nrp1 induction on Tfh cells is associated with B cell survival and correlates "preferentially" with the percentage of plasmablasts but is not associated to any suppressive activity. We found that Nrp1 -and Nrp1 + Tfh cells ex vivo had similar expression of most Tfh associated genes, yet showed differential expression of certain cytokine and surface receptor genes. Finally, we studied Nrp1 expression by malignant Tfhlike cells in cases of angioimmunoblastic T cell lymphoma (AITL). Our data suggest that Nrp1 expression is specifically induced on Tfh cells after contact with cognate B cells in human and correlate with terminal differentiation of B cells. These findings will help our current understanding of T celldependent B cell responses in health and disease.
Methods

Human samples
Tonsils were obtained from children undergoing tonsillectomy. Non-malignant lymph nodes (mesenteric, axillary, cervical, submaxillary and mediastinal) were obtained from patients (age range: 2-25 yrs, median: 14 yrs) with nonspecific reactive follicular hyperplasia validated by histopathological analysis. Briefly, organs were perfused with RPMI 1640 20% FCS, dissociated on a 100 µm nylon membrane, mononuclear cells were obtained after centrifugation over a gradient of Lymphocyte Preparation Medium (PAA) and washed with cold PBS before staining. AITL samples were obtained from cryopreserved lymph node cell suspensions. Participants and next of kin, caretakers, or guardians on the behalf of the minors/children participants provided their written informed consent to participate in this study, which was approved by the Necker Hospital Ethical Committees for human research and were performed according to the European Union guidelines and the declaration of Helsinki.
Flow cytometry
FITC-labeled anti-CD19 (HIB19), APC-labeled anti-CD38 (HB-7), PE-labeled anti-IgD (IA6-2), FITC-labeled anti-CD69 (FN 50), FITC-labeled anti-CD45RA (5H9), Alexa488-labeled anti-Ki67 (B56), 7AAD (all from BD Biosciences), efluor450-labeled anti-CD3 (OKT3), PE-Cy7-labeled anti-CD4 (RPA-TA), PE or FITC-labeled anti-CD25 (BC96) APC-labeled anti-Foxp3 (236A/E7) (all from eBioscience), FITC-labeled anti-CD57 (HCD57), PERCP-Cy5.5-labeled anti-CXCR5 (TG2/CXCR5), FITC-labeled anti-PD1 (EH12.2H7), Alexa647-labeled anti-ICOS (C398.4A), PERCP-Cy5.5-labeled anti-CCR7 (TG8/ CCR7) (all from Biolegend) and PE-or APC-labeled antineuropilin1 (anti-BDCA4, 446921, R&D Systems) were used to stain and analyze T cells and B cells populations. Staining was performed as previously described [25] . Data were acquired on a FACSCanto II flow cytometer (BD Biosciences) using FACSDiva software (BD Biosciences) and were analyzed with FlowJo 8.8.2 software (Treestar).
Cell culture
CD4
+ T cells were isolated from human tonsils using CD4 microbeads (Miltenyi Biotec 24 -well U-bottom tissue culture plates and 0.4 µm BD Falcon cell culture inserts (BD Biosciences) were used. B cell viability was assessed by 7-AAD staining after 5 days of culture and live B cells counted with flow cytometry beads (Accucheck, Invitrogen). IgG, IgA and IgM production in the supernatant were determined after 10-14 days of culture by ELISA according to the manufacturer's protocol (Bethyl). For all experiments, culture medium consisted of RPMI supplemented with 10% FCS, 2mM Lglutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. 
Gene expression analysis
Statistical analysis
Statistical analyses were performed using the appropriate tests, as indicated in the figure legends, using Prism 5.0 software (GraphPad) or Microsoft Excel. In human tonsils, we found Nrp1 to be highly expressed on a subset of CD4 + T cells. Tonsillar CD4 + T cells expressing Nrp1 had a memory phenotype (CD45RA -) and expressed high levels of CD69, but did not express CCR7, excluding their affiliation to the central memory CD4
Results
Nrp1
+ T cell population ( Figure  1 A) . We have already demonstrated that, contrary to mice, Nrp1 expression in human is not associated with expression of CD25 and Foxp3 [25] . Here we confirmed that Nrp1 expression was not associated with CD25 or Foxp3 expression ( -or ICOS lo non-Tfh cells was highly significant once data from multiple donors was analyzed. CD57 is a marker of human GC Tfh cells [27] . Nrp1 was expressed in a higher proportion of CD57 + Tfh cells than of CD57 -Tfh cells ( Figure 1 G and H), suggesting Nrp1 is "preferentially" expressed in Tfh cells located in the GC.
In order to confirm that Nrp1 + T cells belonged to the Tfh cell population, we tested their ability to induce B cell survival and immunoglobulin production in vitro. 
T cells in human tonsils are not proliferating and have no suppressive activity
In previous studies in mice and humans, the expression of Nrp1 in T cells has been associated with either proliferation or suppressive activity [18] [19] [20] [21] [22] [23] [24] [25] . We therefore investigated whether Nrp1 + CD4 + T cells may correspond to a subset of Tfh cells in proliferation or to the recently described Foxp3
+ regulatory Tfh cells [28, 29] . In tonsils, Nrp1 + Tfh cells did not express the proliferation associated marker Ki67, suggesting that these cells are quiescent in vivo (Figure 3 
Nrp1 expression correlates with B cell differentiation in secondary lymphoid organs
To understand the significance of in vivo Nrp1 expression, we compared T and B cell populations in human tonsils and non-malignant reactive lymph nodes. 
Tfh cells
Our correlation studies and in vitro experiments strongly suggested that Nrp1 expression in tonsillar Tfh cells in vivo marked cells that had recently interacted with cognate antigenpresenting B cells and mediating their differentiation. We analyzed the expression of several immunologically relevant genes in ex vivo purified tonsillar Nrp1 -and Nrp1 + Tfh cells to identify key molecular differences between the two subsets ( Figure 6 and Table S1 ). Consistent with both subsets being CXCR5 + Tfh cells, Nrp1 -and Nrp1 + Tfh cells showed high expression of the Tfh-associated genes BCL6, IL21, CXCL13, ICOS, PDCD1 (encoding PD-1), CXCR5, CD40LG (encoding CD40L) and IL6R, but low expression of genes associated with other T helper lineages like FOXP3, TBX21 (encoding T-bet), RORC (encoding ROR-γt), IFNG (encoding IFN-γ), IL2, IL17A, CCR7 and IL2RA (encoding CD25) (Figure 6 A-C) . Moreover, NRP1 expression was restricted to Nrp1 + Tfh cells, thus further confirming the purity of the sorted cell populations (Figure 6 C) . Nrp1 + Tfh cells differed from their Nrp1 -counterparts by expressing significantly less PRDM1 (encoding Blimp-1) and IL10, but more IL4 and TNFSFR18 (encoding GITR) (Figure 6 A-C). Nrp1 + Tfh cells also expressed more CXCL13, more PDCD1, and more IL21R than Nrp1 -Tfh cells, although these differences did not reach statistical significance (Figure 6 B-C) . There was also a significant 2-fold increase in the expression (Table S1 ). These results suggest that cognate contact with B cells in vivo imprints a distinct molecular program in human Tfh cells that goes beyond the upregulation of Nrp1 and likely serves a function in B cell differentiation and the GC reaction.
Nrp1 expression in malignant PD-1 +
Tfh-like cells of angioimmunoblastic T-cell lymphoma (AITL)
Angioimmunoblastic T-cell lymphoma (AITL) is a systemic disease associated with B cell symptoms and expansion of PD-1 + tumoral T cells. Recently, a molecular link between AITL and Tfh cells was described [34, 35] , suggesting that AITL cells were transformed Tfh cells. In this study, we analyzed Nrp1 expression in homogenized lymph node biopsies of five patients (P1-P5) presenting AITL. The clinical and biological parameters of the patients' diseases are detailed in Table 1 . Briefly, all patients but one had autoimmune symptoms, they presented different ECOG status from 0 to 4 (0: fully active, able to carry on all pre-disease performance without restriction; 4: completely disabled, cannot carry on any self-care, totally confined to bed or chair [36] ), three patients were hypergammaglobulinemic, and only one had a significant medullar plasmacytosis. In all cases the malignant CD4 + T cell population expressing PD-1 did not express CXCR5 in contrast to the non-malignant lymph node LN 1 (Figure 7 A and Table   1 Table 1) we observed high levels only in P3. Interestingly, high expression of Nrp1 was only observed in the most severe case of AITL which was associated with a high ECOG score, a high level of gammaglobulin (76 g/L) as well as an important medullar and blood plasmacytosis (40% and 25% respectively) (Figure 7 C and Table 1 ). Thus, Nrp1 may be highly expressed by malignant Tfh-like cells in AITL, and Nrp1 expression may associate with deregulation of B cell differentiation and disease severity.
Discussion
Nrp1 expression in human T cells is restricted to a subset of CD4 + T cells in secondary lymphoid organs. Although Nrp1 + CD4 + T cells may co-express CD25 and exert regulatory function in some cancer-draining lymph nodes [24] , in nonmalignant lymph nodes and tonsils, Nrp1 + CD4 + T cells have a non-regulatory (CD25 -FoxP3 -) memory (CD45RA -CD45RO + ) phenotype [25] . Nrp1 + CD4 + T cells also express the activation marker CD69 and the GC Tfh-related molecule CD57 [32] . In the sanroque mouse model of autoimmunity, massive Tfh differentiation and activity is associated with increased Nrp1 expression at the mRNA level [37] . Our study provides strong phenotypic and functional evidence that Nrp1 + T cells in humans are a subset of Tfh cells: Nrp1 + T cells express all the Nrp1 is induced on human peripheral blood T cells after in vitro activation with strong T cell receptor (TCR) crosslinking [25] . In humoral immune responses, cognate B cell / T cell interactions involving TCR / pMHCII interactions drive plasmablast differentiation, GC B cell development and high affinity B cell selection [38] . In the GC reaction, Tfh cell-based selection of high affinity GC B cells in the light zone induces cell cycle entry, migration to the dark zone, and terminal differentiation into plasma cells [38] . Little is known on the impact of such cognate interactions on Tfh cells. Although B cells are not required for the first stage of Tfh cell differentiation [26] , cognate interactions between antigen-experienced T and B cells reinforce the molecular program of Tfh cells and are required for GC formation [8] . We show here that Nrp1 + Tfh cells have higher expression of IL21R but lower expression of PRDM1 (encoding Blimp-1, a potent negative regulator of Bcl6 and of Tfh cell differentiation [39] ) than Nrp1 -Tfh cells, which suggests that B cell contact during terminal B cell differentiation also re-activates the Tfh differentiation program. Moreover, increased expression of CXCL13, IL4, PDCD1(encoding PD-1), TNFSFR9 (encoding CD137 or 4-1BB) and TNFSFR18 (encoding GITR), as observed in Nrp1 + Tfh cells, may be a signature of cognate B cell contact in Tfh cells. In mice, GC Tfh cells express higher levels of PD-1 and are the main producers of IL-4 [40] . In human, GC Tfh cells produce higher levels of CXCL13 and IL-4, but much less IL-10 than non-GC Tfh cells [41] . Our gene expression analyses show increased expression of IL4, PDCD1 and CXCL13, but reduced expression of IL10, in Nrp1 + Tfh cells compared to their Nrp1 -counterparts. These results suggest that cognate interactions with B cells favor GC Tfh cells differentiation and maintenance in humans. "Preferential" expression of Nrp1 by CD57 + Tfh cells suggests that the phenomenon we describe is mostly concentrated to the GC. However, Nrp1 is also observed on CXCR5 + CD57 -, which implicates that Nrp1 expression is not specific to a subset of Tfh cells, but rather characteristic of an activation state that is induced during, and shortly after, interaction with cognate B cells inside and outside the GC. Nrp1 functions as a homotypic adhesion molecule in immunological synapses involving dendritic cells and CD4 + T cells in human [17] or Treg cells in mice [20] . The absence of Nrp1 expression in B cells, ex vivo or after culture with T cells, makes it unlikely that Nrp1 serves this function in human GCs. In the nervous system, Nrp1 serves as a coreceptor, along with plexin family members, for secreted chemorepellent class 3 semaphorins [14] . In the thymus, Nrp1 and one of its ligands, semaphorin 3A, interact to control the migration of thymocytes along thymic epithelial cells [42, 43] . In mice, GC B cells express axon guidance molecules like plexin B2 [44] . Therefore, it is likely that axon guidance cues and their receptors play a role in the migration of cells in the GC environment. Nrp1 expression in Tfh cells may be necessary for their migration to and/or retention in the GC.
AITL is a peripheral T cell lymphoma that derives from Tfh cells [34, 35, 45] . Our study of five cases of AITL revealed that Nrp1 expression in malignant PD-1 + T cells is not systematic. Only one case had high Nrp1 expression on malignant Tfh-like cells, which was associated with increased gammaglobulinaemia and massive blood and medullary plasmacytosis. This suggests that Nrp1 expression in AITL may be a correlate of increased Tfh-like activity leading to severe B cell symptoms. Nrp1 is expressed in numerous cancer types and is usually associated with a bad prognosis due to its role in tumor angiogenesis and migration [46] . Monoclonal antibodies [47] and small peptides [48, 49] that block Nrp1-mediated functions are being developed as cancer therapeutics. Other strategies that use Nrp1 as an endocytic receptor to target drugs specifically to Nrp1 + cells in the tumor microenvironment also show great promise [50, 51] . Such strategies may prove efficient to target Nrp1 + Tfh cells in the treatment of severe AITL. 
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